24th Dec 2021 08:47
(Alliance News) - Sensyne Health PLC said on Friday it has won two new agreements, with Exscientia and RwHealth, for its data platform Sensight.
Sensight is a clinical artificial intelligence platform that provides industrial-scale access to insights from anonymised and de-identified real-world data across multiple therapy areas, Sensyne explained.
The Oxford-based clinical AI-focused company said its strategic partnership with RwHealth will include subscriptions for ten Sensight seats and RwHealth becoming a Sensight channel partner.
RwHealth is based in London and provides healthcare analytics and information services to UK and international health systems.
The second deal is a one-year agreement with Exscientia to use the Sensyne platform to study health data. Exscientia is an Oxford-based drug discovery company with a focus on AI technology.
Under the agreement, Exscientia will make an upfront payment for four Sensight subscriptions and a project-based fee, with a 40-60 split between the two. Sensyne will then create data sets from its database of patient records to answer project-specific questions regarding biomarker discovery and targets for new medicines.
Shares in Sensyne were up 1.8% at 79.90 pence on Friday morning in London.
By Heather Rydings; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
SENS.L